ADMA Biologics, Inc. announced preliminary unaudited revenues results for the fourth quarter and full year 2020. For the quarter, the company reported revenues of $13.9 million, compared to $12.0 million during the fourth quarter of 2019, reflecting a 16% increase. The preliminary results for the fourth quarter of 2020 represent the company’s highest revenue generating quarter since its inception. For the Full year preliminary unaudited total revenues of $42.2 million, compared to $29.3 million for the full year 2019, reflecting a substantial 44% increase over full year 2019.